Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management

References

• OlfsonMBlancoCLiuSMWangSCorrellCNational trends in the office-based treatment of children, adolescents, and adults with antipsychoticsArch Gen Psychiatry201269121247125622868273
   PubMed Web of Science ®Google Scholar
• BirnbaumMLSaitoEGerhardTPharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implicationsCurr Psychiatry Rep201315382113
   Google Scholar
• SeidaJSchoutenJRBoylanKAntipsychotics for children and young adults: a comparative effectiveness reviewPediatrics20121293771784
   Web of Science ®Google Scholar
• CorrellCUAntipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomesJ Am Acad Child Adolesc Psychiatry200847192018174821
   PubMed Web of Science ®Google Scholar
• MaayanLCorrellCUWeight gain and metabolic risks associated with antipsychotic medications in children and adolescentsJ Child Adolesc Psychopharmacol201121651753522166172
   PubMed Web of Science ®Google Scholar
• MorratoEHDrussBHartungDMMetabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugsArch Gen Psychiatry2010671172420048219
   PubMed Web of Science ®Google Scholar
• ReevesGKeetonCCorrellCUImproving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methodsChild Adolesc Psychiatry Ment Health2013713123947389
   PubMed Web of Science ®Google Scholar
• PringsheimTPanagiotopoulosCDavidsonJHoJEvidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youthPaediatr Child Health201116958158923115502
   PubMed Web of Science ®Google Scholar
• CorrellCUKaneJMOne year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic reviewJ Adolesc Psychopharmacol2007175647656
   PubMed Web of Science ®Google Scholar
• Psychopharmacology InstituteNeurological side effects of antipsychotics: akathisia, dystonia and parkinsonism2013 Available from: http://psychopharmacologyinstitute.com/antipsychotics-videos/neurological-side-effects-akathisia-dystonia-and-parkinsonismAccessed May 12, 2014
   Google Scholar
• CorrellCUGerhardTOlfsonMPrescribing of psychotropic medications to children and adolescents: quo vadis?World Psychiatry201312212712823737416
   PubMed Web of Science ®Google Scholar
• CorrellCUManuPOlshanskiyVNapolitanoBKaneJMMalhotraAKCardiometabolic risk of second-generation antipsychotics during first-time use in children and adolescentsJAMA2009302161765177319861668
   PubMed Web of Science ®Google Scholar
• McVoyMFindlingRClinical Manual of Child and Adolescent Psychopharmacology2nd edArlington (VA)American Psychiatric Publishing2013
   Google Scholar
• De HertMDobbelaereMSheridanEMCohenDCorrellCUMetabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practiceEur Psychiatry201126314415821295450
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionChildhood obesity facts2014 Available from: http://www.cdc.gov/obesity/data/childhood.htmlAccessed May 12, 2014
   Google Scholar
• MaayanLCorrellCUManagement of antipsychotic-related weight gainExpert Rev Neurother20101071175120020586697
   PubMed Web of Science ®Google Scholar
• SikichLFrazierJAMcClellanJDouble-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) studyAm J Psychiatry2008165111420143118794207
   PubMed Web of Science ®Google Scholar
• SarkarSGroverSAntipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysisIndian J Pharmacol201345543944624130376
   PubMed Web of Science ®Google Scholar
• CorrellCKratochvilCMarchJSDevelopments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychoticsJ Clin Psychiatry201172565567021658348
   PubMed Web of Science ®Google Scholar
• CacciaSSafety and pharmacokinetics of atypical antipsychotics in children and adolescentsPediatr Drugs201315217233
   Google Scholar
• CorrellCUSheridanEMDelBellowMPAntipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trialsBipolar Disord201012211614120402706
   PubMed Web of Science ®Google Scholar
• Castro-FornielesJParelladaMGonzalez-PintoAThe child and adolescent first-episode psychosis study (CAFEPS): design and baseline resultsSchizophr Res2007911–222623717267179
   PubMed Web of Science ®Google Scholar
• HaasMUnisASArmenterosJCopenhaverMDQuirozJAKushnerSFA 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophreniaJ Child Adolesc Psychopharmacol200919661162120035579
   PubMed Web of Science ®Google Scholar
• HaasMEerdekensMKushnerSEfficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind studyBr J Psychiatry200919421586419182179
   PubMed Web of Science ®Google Scholar
• HaasMDelBelloMPPandinaGRisperidone for the treatment of acute mania in children and adolescents with bipolar disorder:a randomized, double-blind, placebo-controlled studyBipolar Disord200911768770019839994
   PubMed Web of Science ®Google Scholar
• PalvuluriMNHenryDBFindlingRLDouble-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorderBipolar Disord201012659360520868458
   PubMed Web of Science ®Google Scholar
• SheaSTurgayACarrollARisperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disordersPediatrics20041145634641
   PubMed Web of Science ®Google Scholar
• PandinaGJBossieCAYoussefEZhuYDunbarFRisperidone improves behavioral symptoms in children with autism in arandomized, double-blind, placebo-controlled trialJ Autism Dev Disord200737236737317019624
   PubMed Web of Science ®Google Scholar
• GhanizadehASahraeizadehABerkMAHead-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trialChild Psychiatry Hum Dev201445218519223801256
   PubMed Web of Science ®Google Scholar
• MargariLMateraECraigFTolerability and safety profile of risperidone in a sample of children and adolescentsInt Clin Psychopharmacol201328417718323689836
   PubMed Web of Science ®Google Scholar
• FindlingRLRobbANyilasMA multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophreniaAm J Psychiatry2008165111432144118765484
   PubMed Web of Science ®Google Scholar
• FindlingRLNyilasMForbesRAAcute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: arandomized, double-blind, placebo-controlled studyJ Clin Psychiatry200970101441145119906348
   PubMed Web of Science ®Google Scholar
• MarcusRNOwenRKamenLA placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorderJ Am Acad Child Adolesc Psychiatry200948111110111919797985
   PubMed Web of Science ®Google Scholar
• OwenRSikichLMarcusRNAripiprazole in the treatment of irritability in children and adolescents with autistic disorderPediatrics200912461533154019948625
   PubMed Web of Science ®Google Scholar
• FindlingRLMankoskiRTimkoKRandomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorderJ Clin Psychiatry2014751223024502859
   PubMed Web of Science ®Google Scholar
• FindlingRLMcKennaKEarleyWRStankowskiJPathakSEfficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trialJ Child Adolesc Psychopharmacol201222532734223083020
   PubMed Web of Science ®Google Scholar
• ArangoCRoblesOParelladaMOlanzapine compared to quetiapine in adolescents with a first psychotic episodeEur Child Adolesc Psychiatry200918741842819198920
   PubMed Web of Science ®Google Scholar
• JensenJKumraSLeittenWA comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disordersJ Child Adolesc Psychopharmacol200818431732618759641
   PubMed Web of Science ®Google Scholar
• PathakSFindlingRLEarleyWRAcevedoLDStankowskiJDelbelloMPEfficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trialJ Clin Psychiatry2013741e100e10923419231
   PubMed Web of Science ®Google Scholar
• DelBelloMPKowatchRAAdlerCMA double-blind randomized pilot study comparing quetiapine and divalproex for adolescent maniaJ Am Acad Child Adolesc Psychiatry200645330531316540815
   PubMed Web of Science ®Google Scholar
• ConnorDFMcLaughlinTJJeffers-TerryMRandomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorderJ Child Adolesc Psychopharmacol200818214015618439112
   PubMed Web of Science ®Google Scholar
• KryzhanovskayaLSchulzSCMcDougleCOlanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trialJ Am Acad Child Adolesc Psychiatry2009481607019057413
   PubMed Web of Science ®Google Scholar
• TohenMKryzhanovskayaLCarsonGOlanzapine versus placebo in the treatment of adolescents with bipolar maniaAm J Psychiatry2007164101547155617898346
   PubMed Web of Science ®Google Scholar
• AgidORemingtonGKapurSArenovichTZipurskyRBEarly use of clozapine for poorly responding first-episode psychosisJ Clin Psychopharmacol200727436937317632221
   PubMed Web of Science ®Google Scholar
• SchneiderCCorrigallRHayesDKyriakopoulosMFrangouSSystematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophreniaEur Psychiatry201429111024119631
   PubMed Web of Science ®Google Scholar
• FindlingRLCavuşIPappadopulosEEfficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorderJ Child Adolesc Psychopharmacol201323854555724111980
   PubMed Web of Science ®Google Scholar
• CorrellCULopsJDFigenVMalhotraAKKaneJMManuPQT interval duration and dispersion in children and adolescents treated with ziprasidoneJ Clin Psychiatry201172685486021457682
   PubMed Web of Science ®Google Scholar
• StromBLEngSMFaichGComparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)Am J Psychiatry2011168219320121041245
   PubMed Web of Science ®Google Scholar
• SinghJRobbAVijapurkarUNuamahIHoughDA randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescentsBiol Psychiatry201170121179118721831359
   PubMed Web of Science ®Google Scholar
• DeHertMWeipingYDetrauxJSweersKvan WinkelRCorrellCBody weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysisCNS Drugs201226973375922900950
   PubMed Web of Science ®Google Scholar
• BonfioliEBertiLGossCMuraroFBurtiLHealth promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomized controlled trialsBMC Psychiatry2012127822789023
   PubMed Web of Science ®Google Scholar
• Alvarez-JiménezMMartínez-GarcíaOPérez-IglesiasRRamírezMLVázquez-BarqueroJLCrespo-FacorroBPrevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trialSchizophr Res20101161161919896336
   PubMed Web of Science ®Google Scholar
• DaumitGDalcinATJeromeGJA behavioral weight-loss intervention in persons with serious mental illnessN Engl J Med2013388171594160223517118
   PubMed Web of Science ®Google Scholar
• American Medical AssociationRecommendations on the assessment, prevention, and treatment of childhood obesity2007 Available from: http://www.ama-assn.org/ama/pub/physician-resources/public-health/promoting-healthy-lifestyles/obesity/childhood-obesity/assessment-prevention-treatment.page?Accessed May 12, 2014
   Google Scholar
• BuckleyPFCorrellCUStrategies for dosing and switching antip-sychotics for optimal clinical managementJ Clin Psychiatry200869Suppl 1417
   Google Scholar
• FiedorowiczJGMillerDDBishopJRCalargeCAEllingrodVLHaynesWGSystematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizersCurr Psychiatry Rev201281253622712004
   PubMedGoogle Scholar
• CorrellCSikichLReevesGRiddleMMetformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?Am J Psychiatry2013120994795224030606
   PubMed Web of Science ®Google Scholar